ERBB2 and gastric cancer: Fam-trastuzumab-deruxtecan-nxki (T-DXd) was evaluated in the phase II DESTINY-Gastric 01 trial, where it was compared with chemotherapy (irinotecan or paclitaxel) in HER2-positive advanced gastric cancer patients previously treated with at least two lines of therapy, including trastuzumab [70].